X0306 4 2016-06-21 1 0001344413 Alexza Pharmaceuticals Inc. ALXA 0001316623 Read J Leighton C/O ALEXZA PHARMACEUTICALS, INC. 2091 STIERLIN COURT MOUNTAIN VIEW CA 94043 1 0 0 0 Common Stock 2016-06-21 4 U 0 3492 D 0 D Stock Option (right to buy) 1.28 2016-06-21 4 D 0 12500 0.00 D 2016-06-03 2025-06-22 Common Stock 12500 0 D Stock Option (right to buy) 4.35 2016-06-21 4 D 0 12500 0.00 D 2015-06-10 2024-06-09 Common Stock 12500 0 D Stock Option (right to buy) 4.68 2016-06-21 4 D 0 11606 0.00 D 2013-06-21 2023-05-20 Common Stock 11606 0 D Stock Option (right to buy) 3.50 2016-06-21 4 D 0 3991 0.00 D 2012-07-06 2022-06-06 Common Stock 3991 0 D Stock Option (right to buy) 15.30 2016-06-21 4 D 0 3125 0.00 D 2011-08-28 2021-07-28 Common Stock 3125 0 D Stock Option (right to buy) 35.20 2016-06-21 4 D 0 625 0.00 D 2010-06-18 2020-05-18 Common Stock 625 0 D Stock Option (right to buy) 16.90 2016-06-21 4 D 0 625 0.00 D 2009-06-07 2019-05-07 Common Stock 625 0 D Stock Option (right to buy) 53.30 2016-06-21 4 D 0 625 0.00 D 2008-06-27 2018-05-27 Common Stock 625 0 D Stock Option (right to buy) 98.50 2016-06-21 4 D 0 625 0.00 D 2007-06-23 2017-05-23 Common Stock 625 0 D Per the terms of the Agreement and Plan of Merger, dated 5/9/16, among the Issuer, Grupo Ferrer Internactional, S.A. and Ferrer Pharma Inc. (the "Agreement) and the Offer (as defined in the Agreement), each share of the Issuer's common stock was tendered for $0.90 per share in cash, without interest and less any required withholding taxes, plus one contractual contingent value right per share ("CVR") (as defined in the Agreement). Disposed of per Section 3.4(a) of the Agreement, whereby each option that was outstanding immediately prior to the Offer Closing (as defined in the Agreement) was cancelled without consideration. /s/ Brent D. Fassett, as Attorney-in-Fact for J. Leighton Read 2016-06-21